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Photoactivation of lysosomally sequestered sunitinib
after angiostatic treatment causes vascular occlusion
and enhances tumor growth inhibition
P Nowak-Sliwinska*,1,5, A Weiss1,2,5, JR van Beijnum2, TJ Wong2, WW Kilarski3, G Szewczyk4, HMW Verheul2, T Sarna4,
H van den Bergh1 and AW Griffioen*,2
The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have
previously shown that sunitinib is sequestered in the lysosomes of exposed tumor and endothelial cells. This phenomenon is part
of the drug-induced resistance observed in the clinic. Here, we demonstrate that when exposed to light, sequestered sunitinib
causes immediate destruction of the lysosomes, resulting in the release of sunitinib and cell death. We hypothesized that this
photoactivation of sunitinib could be used as a vaso-occlusive vascular-targeting approach to treating cancer. Spectral properties
of sunitinib and its lysosomal accumulation were measured in vitro. The human A2780 ovarian carcinoma transplanted onto the
chicken chorioallantoic membrane (CAM) and the Colo-26 colorectal carcinoma model in Balb/c mice were used to test the effects
of administrating sunitinib and subsequently exposing tumor tissue to light. Tumors were subsequently resected and subject to
immunohistochemical analysis. In A2780 ovarian carcinoma tumors, treatment with sunitinib+light resulted in immediate specific
angio-occlusion, leading to a necrotic tumor mass 24 h after treatment. Tumor growth was inhibited by 70% as compared with
the control group (**Po0.0001). Similar observations were made in the Colo-26 colorectal carcinoma, where light exposure of the
sunitinib-treated mice inhibited tumor growth by 50% as compared with the control and by 25% as compared with sunitinib-only-
treated tumors (N≥ 4; P= 0.0002). Histology revealed that photoactivation of sunitinib resulted in a change in tumor vessel
architecture. The current results suggest that the spectral properties of sunitinib can be exploited for application against certain
cancer indications.
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Angiogenesis inhibitors are currently firmly implemented in
the clinical management of cancer. For example, sunitinib has
been approved for the treatment of advanced renal cell
carcinoma (RCC),1 gastrointestinal stromal tumors (GIST)2
and pancreatic neuroendocrine tumors.3 Studies assessing its
activity against other tumor types are currently underway.4
Sunitinib was developed as an angiogenesis inhibitor5 and
revolutionized the management of advanced RCC and GIST.
Its mode of action is based on the suppression of the tyrosine
kinase activity of several growth factor receptors, mainly
VEGFR2 and PDGFR (alpha and beta).6 It has been
previously shown that sunitinib is sequestered by tumor
cells in their lysosomal compartments.7 This sequestration,
which limits the exposure of other parts of the cell to sunitinib,
is part of a drug-induced resistance mechanism that
has also been clinically observed.7 The sequestration and
accumulation of sunitinib in the lysosomes is similar to a
phenomenon that has been described for certain other
chemotherapeutics8,9 or photosensitizing compounds,10 and
depends, at least to some extent, on the hydrophobic
and weak basic features of the molecule. We discovered a
particular characteristic of sunitinib based on its optical
properties, which may be helpful in the treatment of certain
cancers. On the basis of the spectral features of sunitinib, we
hypothesized that the drug may have photosensitizer-like
properties.11 If so, exposure to light of an appropriate
wavelength could lead to the disruption of the lysosomal
membrane, the release of sunitinib and re-exposure of the
cell to this molecule. This could lead to further cell damage and
eventually cell death. In this study, we show that the exposure
of sunitinib-treated cells to light of an appropriate wavelength
excites the molecule, which leads to the generation of reactive
oxygen species (ROS). We show in two tumor models, that is,
human ovarian carcinoma (A2780) xenografted on the
chorioallantoic membrane of the chicken embryo (chicken
chorioallantoic membrane (CAM)) and in colorectal carcinoma
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in Balb/c mice, that treatment with sunitinib and its subsequent
photoexcitation leads to significant occlusion of the vascula-
ture and inhibition of tumor growth. Our results indicate that
additional antitumor activity can be obtained after the normal
use of sunitinib through its use as a photosensitizer and the
application of light. The combination of classical sunitinib-
induced angiostasis with the re-exposure of tumor cells to
sunitinib after the destruction of lysosomes and photodynamic
vessel obstruction can lead to a strategy that may be
applicable in patients.
Results
Spectral properties of sunitinib and its sequestration in
endothelial cell lysosomes. Absorption and emission
spectra of sunitinib were generated in an aqueous solution
(Figure 1a). Sunitinib light absorbance was found to be in a
broad range of 340–480 nm, with the absorption maximum at
429 nm. Sunitinib showed strong fluorescence with a max-
imum at 540 nm. Fluorescence microscopy revealed that
incubating human umbilical vein endothelial cells (HUVEC) in
1 μM sunitinib for an hour resulted in the sequestration of
sunitinib in subcellular compartments. Sunitinib, being a
hydrophobic weak base (acid dissociation constant of 8.95),7
was predominantly localized in the lysosomes of the cells. A
near-100% colocalization of sunitinib and lysotracker fluor-
escence supported this observation (Figure 1b). Uptake of
sunitinib in endothelial cells was observed as early as 10 s
after exposure, with visible accumulation in lysosomes after
30 s (Figure 1c).
Light exposure of endothelial cells with sequestered
sunitinib induces cell cytotoxicity. HUVEC cells were
incubated with sunitinib (1 μM) for 1 h at 37 °C, to allow
sufficient amounts of sunitinib being sequestered in the
lysosomes. Cells were then washed with drug-free medium
and subjected to illumination for a time period of 5 min under
a fluorescence microscope with excitation wavelengths of
420±20 nm and emission wavelengths of 4470 nm. Upon
light illumination, a rapid destruction and disappearance of
sunitinib-containing lysosomes was observed (200mW/cm2,
Figure 2a). Over 3 min of light exposure, 470% of the
sunitinib-containing lysosomes disappeared (Figure 2a,
quantification Figure 2b), whereas 490% of lysosomes were
destroyed after 5 min (a movie of this experiment can be
viewed at the secured site: www.angiogenesis.nl/Nowak
Sliwinska%20submission.htm). The destruction of lysosomes,
visible as multiple asynchronous flashes, was accompanied
by a gradual increase in cytoplasmic and nuclear fluores-
cence (λem= 405 nm). After 180 s of light exposure, nuclear
fluorescence increased over sevenfold, whereas the cyto-
plasmic fluorescence increased over 13-fold (images in
Figure 2a, quantification in Figure 2c). Nuclear localization
of sunitinib was further confirmed using confocal microscopy
(Supplementary Figure 1A). Quantification of the sunitinib in
a z-stack of images (Supplementary Figure 1A) showed
higher sunitinib accumulation in the nuclei of cells as
compared with the cytoplasm (Supplementary Figure 1B).
Interestingly, within the nucleus, sunitinib appeared to
accumulate preferentially in or associated to the nucleoli
(Figures 2c and d). A subsequent trypan blue exclusion
assay revealed that the light-exposed cells were dead
(Figure 2e), whereas cells exposed to sunitinib or light only
(Supplementary Figure 2) were still capable of dye exclusion.
The absorption spectrum of sunitinib before and after light
exposure showed no significant changes in the absorbance
peaks, suggesting that light exposure did not lead to structural
changes or damage of sunitinib molecules (Supplementary
Figure 3), a result that was similar for the clinically approved
photosensitizer Visudyne (Novartis Pharma Inc., Hettlingen,
Switzerland). These results suggest that sunitinib has
photosensitizer-like activity, such as light-induced generation
of ROS. To verify this, we measured the singlet oxygen
generation (type-II photochemistry) of sunitinib by direct
detection of its phosphorescence at 1270 nm, after pulsed
excitation with 355 nm laser radiation in acetonitrile and
DMSO (Sigma-Aldrich, Buchs, Switzerland). The quantum
yield of singlet oxygen formation was 5–7% of the quantum
yield of tetraanilinoporphyrin (TAP; absolute yield of singlet
oxygen generation is 0.7), used as a positive control
(Figure 2f). It should be noted that the excitation wavelength
of 355 nm is well below the excitation peak of sunitinib at
429 nm. Therefore, in this experiment the induction of singlet
oxygen may be an underrepresentation of the real effect.
Measurement of other ROS using EPR-spin trapping and
DMPO as a spin trap12,13 revealed no induction of ROS. More
information is in the Supplementary Material. The results
suggest that sunitinib-dependent lysosomal photodestruction
Figure 1 Spectral properties of sunitinib and lysosomal accumulation in endothelial cells. (a) Normalized absorption and emission spectra of sunitinib in 0.1% DMSO in 0.9%
NaCl. (b) Colocalization of sunitinib (green) and lysotracker (red) in cultured human umbilical vein endothelial cells (HUVEC). Bar in left panel represents 10 μm. (c) Rapid uptake
and lysosomal accumulation of sunitinib in HUVEC. Bar in left panel represents 5 μm
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is mediated, at least in part, by the generation of singlet
oxygen, leading to the rapid rupture of the lysosomal
membrane, resulting in the release of sunitinib into the
cytoplasm and nucleus, leading to toxicity and cell death.
Photoexcitation of accumulated sunitinib causes
vascular occlusion in the CAM. The CAM model was
used to check for a vascular component in photoactivation of
sunitinib. Sunitinib (12 μg/embryo) was administered i.v. 1 min
prior to light exposure (sunitinib excitation λex=420± 20 nm
was performed with a light fluence of 130 J/cm2 and
irradiance of 270mW/cm2; sunitinib fluorescence was
detected with λem4520 nm; Figure 3a, first image). One
minute after its i.v. injection, sunitinib is already beginning to
accumulate in the endothelium (data not shown). The light
activation of sunitinib at the applied conditions resulted in
complete capillary bed occlusion within the treated area,
which was still visible 24 h after treatment, as shown in the
fluorescein isothiocyanate (FITC)-dextran angiography
(λex=420±20 nm, λem4520 nm, Figure 3a, top right image).
Quantification of the vascular changes was preformed based
on image analysis within four concentric circles (within the
illumination zone for light-treated samples, see Figure 3b),
and is presented as a number of branching points per mm2.
The analysis revealed a 98% reduction of blood vessels in
photo-exposed areas 1 (**P= 0.0015) and 2 (**P= 0.0015),
95% in area 3 (**P=0.0017, t-test), and an approximate 70%
reduction in area 4 (**P= 0.008, Figure 3c) for sunitinib+light
versus light only. Application of light alone did not have any
vaso-occlusive effect. Sunitinib alone resulted in a moderate
Figure 2 Photoactivation of lysosomal sunitinib causes endothelial cell death. (a) Cellular localization of sunitinib in endothelial cells, after 1 h of exposure to 1 μM sunitinib,
visualized by differential interference contrast and fluorescence microscopy (left panel, bar represents 5 μm) at different time points. Arrows indicate ruptured lysosomes.
(b) Quantification of lysosomes (N= 4 cells). (c and d) Gradual increase in cytoplasmic and nuclear and nucleoli-associated fluorescence. Values are normalized to background
fluorescence at each time point to account for photobleaching (N= 4 cells). (e) Trypan blue staining of HUVEC cells incubated for 1 h in 1 μM sunitinib and irradiated with light
(λex= 420 nm) for 60 min. Bar represents 50 μm. (f) Singlet oxygen quantum yield of sunitinib, measured by photoexcitation and detection of phosphorescence at 355 nm.
TAP was used as a positive control. *P= 0.02; **Po0.008
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but significant reduction of branching points in all quantified
zones (**Po0.01). Sunitinib+light significantly reduced the
number of branching points in zone 1 (**P=1.7E−07) and
zone 2 (*P=0.0039) as compared with sunitinib alone.
The angio-occlusive potential of photoactivated sunitinib
was also assessed with a lower dose of sunitinib and a lower
light fluence. An i.v. dose of only 2 ng/embryo, 1min prior
to low-dose light exposure (λex=420±20 nm, 34 J/cm
2,
70mW/cm2) already caused a significant vaso-occlusion in
60–70% of the capillaries (Supplementary Figure 4).
Photoactivation of sunitinib leads to tumor growth
inhibition of A2780 human ovarian carcinoma grown on
the CAM. Human A2780 ovarian carcinoma spheroids were
transplanted onto the CAM and treated as presented in
Figure 4a. Vascularized tumors were detected 3 days post
implantation (Figure 4b, left and middle panels). Tumors
were divided into four treatment groups: (i) control, (ii) light,
(iii) sunitinib, or (iv) sunitinib+light. Treatment was given once
at day 3. Twenty-four hours post treatment with sunitinib+
light, the tumor vasculature was majorly unperfused, as
visualized by fluorescence angiography (Figure 4b, right
panel). The growth of tumors treated with sunitinib+light
(group iv) was inhibited by ~ 70% (**Po0.0001, ANOVA,
N=12) versus control tumors (group i) (Figure 4c). Sunitinib
administered alone inhibited growth by 32% (*P=0.026,
N=3). Immunohistochemical staining showed areas of tumor
destruction and necrosis-associated hemorrhages in the
tumors treated with sunitinib+light (Figure 4d, right image).
Quantification of CD31 staining (Figure 4e) revealed reduced
vessel density in the sunitinib and the sunitinib+light groups,
reaching only significance in the latter group (**Po0.01).
Vascular disruption, observed by a discontinuous endothelial
lining, was significantly increased in the sunitinib+light group,
as compared with the control and sunitinib-treated groups
(**Po0.01 versus control, *P= 0.04 for sunitinib versus
sunitinib+light; Figure 4d, bottom images, and quantification
in Figure 4e).
Photoactivation of sunitinib inhibits tumor growth in a
colon carcinoma mouse model. Balb/c mice were inocu-
lated on the flanks with murine Colo-26 colorectal carcinoma
cells. Four experimental groups were executed: controls,
sunitinib only (i.p. 40mg/kg daily), light only (fluence of
100 J/cm2 and a delivered irradiance of 100mW/cm2) and
sunitinib+light. When tumor size reached approximately
5–6mm in diameter (day 5 after inoculation), treatment of
the mice was started (for 8 days, see Figure 5a). Light was
always applied 3 h after sunitinib administration. Tumor
growth was monitored every day and mice were killed on
day 9 and tumors were resected. Tumor growth was
significantly inhibited by 33% when treated with sunitinib
alone (**Po0.0001) versus CTRL. Although light therapy
alone did not have any effect on tumor growth (P=0.95
versus CTRL), the combination of sunitinib and light resulted
in a significant enhancement of tumor growth inhibition
(**P= 0.0002 versus sunitinib only, Figure 5b). Quantification
of microvessel density in the superficial area of treated
tumors (Figure 5c) revealed a slight but not significant
decrease in the number of blood vessels (Figure 5d).
However, the architecture of the vessels in both groups was
found to be different with a significant decrease in the number
of vessels with an open lumen (*Po0.02) in the sunitinib
+light-treated tumors (Figure 5d). This suggests that the
combined treatment resulted in obstruction of the blood flow
and tissue damage.
Discussion
We have previously shown that sunitinib is taken up by
tumor cells, where it is sequestered and accumulated in
the lysosomal compartment.7 This sequestration has a role in
protection against sunitinib toxicity and more importantly,
in the development of resistance against sunitinib.
Here we show that sunitinib is also sequestered in the
lysosomes of endothelial cells in vitro and in the endothelium
of tumor microvasculature. The photoactivation of seques-
tered sunitinib in vitro resulted in almost immediate
Figure 3 Vascular effects after photoactivation of sunitinib observed in the CAM model. (a) Sunitinib fluorescence after i.v. administration (12 μg/embryo, 1 min prior to light
exposure, λex= 420± 20 nm, 270 mW/cm
2). Representative FITC-dextran fluorescence angiography (12 μg/embryo, 20 kDa, λex= 470 nm, λem= 520 nm) before (left image,
upper row), 24 h after sunitinib and light treatment (right image, upper row), 24 h post light-only treatment (left image, bottom row) and 24 h post administration of sunitinib only
(12 μg/embryo, right image, bottom row). Bar represents 500 μm. (b) Fluorescence angiogram of non-treated CAM vasculature at embryo development day 13. Circles indicate
the four quantification zones used in image processing. (c) Quantification of branching points/mm2 for areas 1–4, as shown in c. Results are expressed as means±S.E.M.,
N= 2–4. Sunitinib alone resulted in a moderate but significant reduction of branching points in all quantified zones (**Po0.01, t-test). Sunitinib+light significantly reduced the
number of branching points in zone 1 (**P= 1.7E− 07, t-test) and zone 2 (*P= 0.0039, t-test) as compared with sunitinib alone
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rupture of the lysosomes, seen as ‘exploding’ vesicles
(see Supplementary Video at www.angiogenesis.nl/
NowakSliwinska%20submission.htm), followed by release
of sunitinib into the cytosol and the nucleus, resulting in
additional cytotoxic effects. The same phenomenon applied
in vivo on the vasculature of the CAM model resulted in
photoinduced vascular obstruction, similar to that seen with
clinically used photosensitizers during vascular-targeted
photodynamic therapy, such as Visudyne.14 Exposure of
sunitinib-treated tumors to an appropriate wavelength of light
significantly enhanced tumor growth inhibition in two separate
preclinical tumor xenograft models for ovarian and colorectal
carcinomas. Ovarian carcinoma tumors grown on the CAM
provide an ideal, easily accessible model to examine the
effects of photoactivated sunitinib in vivo, because the small
superficial tumor allowed for direct light irradiation compen-
sating for limited light penetration depth in tissue at this
wavelength. As it was demonstrated that sunitinib accumu-
lates in both tumor7 and endothelial cells, the observed effect
after exposing the tumors of sunitinib-treated animals to light
is the resultant effect on damage to both tumor and endothelial
cell compartments.
For most current clinical applications, however, the peak
excitation wavelength of sunitinib at 420 nm remains proble-
matic. First, this excitation spectrum largely overlaps with the
absorption spectrum of hemoglobin.15 Thus, in well-perfused
tissues, hemoglobin will absorb a large part of the light energy.
For application in vascularized tissues there are, however,
suboptimal excitation wavelengths, outside the spectrum of
hemoglobin that would still specifically excite sunitinib.
In addition, the excitation wavelength of 420 nm has a limited
tissue penetration depth of ~ 2mm, depending on the tissue.
Modern photosensitizers, such as the chlorine- or porphyrin-
type compounds, have excitation wavelengths in the near-
infrared part of the spectrum, where penetration depth is
significantly higher for the red light than for blue light.16 This
limits the possible application of such a treatment for cancer to
superficial lesions. However, the activation of sunitinib in
deeper tissues may be achievable through (i) two-photon
excitation or (ii) its conjugation with another photosensitizer
(see Figure 6). A marked increase in light transmission
through tissue can be achieved when using light at 800 nm
as comparedwith 400 nm.17 Exciting sunitinib by near-infrared
light through a two-photon strategy may solve the tissue
Figure 4 Photoinduced cytotoxicity of sunitinib in A2780 ovarian carcinoma grown on the CAM. (a) Experimental design. (b) Bright-field image of A2780 tumors grown on the
CAM (left image). FITC-dextran angiograms of the sunitinib-treated A2780 tumors prior to light exposure (middle image) and 24 h post light exposure (right image). Bar represents
1 mm. (c) Relative tumor growth curves of control tumors (CTRL, treated with 0.1% DMSO) and tumors treated with sunitinib on day 3, with or without subsequent light exposure.
Tumor volume was normalized by the respective tumor volume on the first day of treatment and represented as the mean tumor volume± S.E.M. A two-way ANOVA test was
performed versus CTRL (N= 14) with the following results: sunitinib+light (**Po0.0001, N= 12), sunitinib (*P= 0.026, N= 3) and light alone (not significant, N= 2).
(d) Representative images of immunohistochemical staining for CD31 of tumors resected on the last day of the experiment. Red arrow indicates vessel with discontinuous
endothelial lining. (e) Quantification of vessel densities (per mm2) and the percentage of blood vessels with discontinuous vessel endothelium in the CTRL, sunitinib+light and
sunitinib-treatment groups; results are expressed as means± S.E.M. **Po0.01, N= 3–5 images
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penetration issue. Alternatively, other methods can also be
used to increase the wavelength of excitation, such as using a
chromophore capable of two-photon absorption as a ‘photon
harvester’, which could then transfer the appropriate energy to
sunitinib and excite it. On the other hand, it may be questioned
why patients on sunitinib do not have problems with exposure
to sunlight. The answer to this is the fact that the excitation
wavelength of sunitinib, being in the range of 420 nm, is only
Figure 5 Inhibition of tumor growth in Colo-26 murine colon carcinoma tumors. (a) Experimental design. (b) Tumor growth curves of the CTRL, light-only, sunitinib-only and
sunitinib+light groups. Tumor growth was significantly inhibited by treatment with sunitinib alone (**Po0.0001) versusCTRL. Light therapy did not have any effect on tumor growth
(P= 0.95 versus CTRL), whereas the combination of sunitinib and light resulted in a significant enhancement of tumor growth inhibition (**Po0.0002 versus sunitinib only,
ANOVA), N≥ 4. Results are expressed as means±S.E.M. (c) Immunohistochemical staining for blood vessels with CD31 antibody. (d) Quantification of microvessel density and
the number of vessels with an open lumen. Results are expressed as means± S.E.M.
Figure 6 Schematic representation of how to ameliorate sunitinib photoactivation to increase the therapeutic benefit and overcome resistance. This can be done by (a) using
two-photon (2p) excitation and/or (b) conjugation of sunitinib to a photosensitizer with long-wave excitation spectrum
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minutely represented in the solar spectrum. In addition, most
of it is filtered away by the atmosphere. Another strategy
could be conjugation of sunitinib with the photosensitizers
known to undergo the lysosomal internalization process and
characterized by longer, more appropriate light spectra
(infrared spectrum region) for excitation.
The lysosomal sequestration of sunitinib, which is a result
of its weak basic feature, and its accumulation, due to the
protonation of the molecule inside the lysosome, is not
unique to sunitinib. The accumulation of other compounds
in lysosomes and endocytic vesicles has already been
described8,18–21 and it has recently been suggested to involve
the activity of P-glycoprotein.22 This general response of cells
to store toxic compounds in lysosomes suggests a mechan-
ism to protect other cell organelles and processes. The
importance of the vascular compartment in a tumor, or in any
other tissue, may therefore be reflected by the large number of
lysosomes and endocytic vesicles in endothelial cells.
Importantly, photodestruction of the lysosomes resulted in a
concomitant release of sunitinib, eventually resulting in cell
death. This cell death can be caused by interaction with the
primary targets, for example, the vascular endothelial growth
factor (VEGF)/platelet-derived growth factor (PDGF) recep-
tors, or alternatively, through a toxic side effect induced by the
sudden high concentrations of drug in the cytoplasm. In this
context, the recent finding of Ellegaard et al.23 may be
relevant. These authors have shown that sunitinib inhibits acid
sphingomyelinase to destabilize lysosomes, a mechanism
that may be instrumental in the cytotoxic effects observed.
Through these effects, photoactivation of sequestered suniti-
nib may additionally provide a means to target drug-resistant
sub-populations of cells, as it has been shown that there is a
significant increase in the accumulation of lysosomally
sequestered sunitinib in sunitinib-resistant cell cultures as
compared with non-resistant parent cell cultures 24 h after
incubation with sunitinib.7
In the field of photodynamic therapy, several photosen-
sitizers have been shown to exert activity through their
accumulation in lysosomes.9,24,25 Photosensitizers are char-
acterized by their spectral properties and their features to be
excitable by light, to generate ROS, such as singlet oxygen or
oxidizing radicals, and to exert a cytotoxic activity.11 Sunitinib
was known to be fluorescent, but a photosensitizing capacity
has never been demonstrated.
We found that when excited by light, sunitinib was capable
of generating singlet oxygen molecules. Although this activity
was relatively weak compared with clinically used photosen-
sitizers, it seemed sufficient to provoke significant biological
effects. It is important to realize that the overall biological effect
of a photodynamic process depends not only on the efficiency
of the photosensitizer to generate ROSbut also on the location
of the photosensitizer molecules in relation to critical biological
targets. The low yield of ROS, such as short-lived singlet
oxygen, could in part be compensated by close proximity of
the generated ROS to molecular targets, which increases the
probability of their interaction. It should also be noted that in
our study, the measurements of ROS and singlet oxygen was
performed in solution at clinically relevant doses, concentra-
tions that could significantly deviate from the accumulated
dose in the lysosomes. Extraction of sunitinib from human
tumors revealed that concentrations can be 10-fold higher, as
compared with the serum.7 Considering the fact that the
lysosomal volume may be less than 1% of the volume of the
cell, the concentration of sunitinib in a lysosome may be well
over 1000-fold higher than in the serum of a cancer patient.
This may explain why a successful treatment was achieved,
even with the relatively low generation of singlet oxygen
molecules.
Major applications of phototherapy are in superficial
tumors mainly in the skin and hollow organs, due to the lack
of penetration of sufficient light irradiation in deeper tissues.
Applications are also possible in transparent parts of the
human body, such as the eye. Such applications are used
as the principal treatment for polypoidal choroidal
vasculopathy,26 certain cases of age-related macular degen-
eration and several ocular tumors.27 Phototherapy is also used
for skin cancers, including basal cell carcinoma and squamous
cell carcinoma.28–30 The combination of phototherapy and
angiogenesis inhibition, either before light exposure to
generate a vascular normalization window31 or after,32 in a
single drug suggests a benefit for successful application in
patients. Alternatively, the capacity of low-dose sunitinib
photoactivation as a means of induced vascular leakage and
forced delivery of drugs into tumorsmay also be considered for
therapeutic approaches in the clinic.
Materials and Methods
Sunitinib preparation and spectroscopy. Stock solutions of the free
form of sunitinib (sunitinib malate, Pfizer Inc., New York, NY, USA) were prepared in
100% DMSO (Sigma-Aldrich). Dilutions were made in 0.9% NaCl under continuous
stirring. Visudyne (Novartis Pharma Inc.) was dissolved in 5% glucose and diluted in
NaCl. Absorption spectra were recorded with a two-beam Varian Cary UV-Vis-NIR
500 Scan spectrophotometer in 1-cm-long quartz cuvettes (Suprasil, Hellma,
Müllheim, Germany) between 350 and 800 nm with an average scan speed
of 600 nm/min at 20 °C. The steady-state luminescence spectra were recorded with
a luminescence spectrometer (Perkin-Elmer, model LS50B, Waltham, MA, USA).
Cell culture and cellular localization of sunitinib and image
quantification. Primary HUVECs were isolated from umbilical cords and
cultured in RPMI-1640 (Life Technologies, Breda, The Netherlands) supplemented
with 10% heat-inactivated human and 10% heat-inactivated fetal bovine serum,
2 mM L-glutamin (Life Technologies), 50 mg/ml streptomycin and 50 U/ml penicillin
(ICN Biomedicals, Santa Ana, CA, USA) in a 0.2% gelatin-coated tissue culture
flasks at 37 °C at 5% CO2, cells were seeded at a density of 4 × 10
4 cells/well in
96-well plates. Cells were incubated with 1 μM sunitinib, washed and the cellular
localization of sunitinib was evaluated by fluorescence microscopy. Cells were
imaged using differential interference contrast microscopy using an Axio Observer
microscope at 405 nm (Carl Zeiss, Oberkochen, Germany). Lysosomal sequestra-
tion was confirmed by incubation with 25 nM Lysotracker Red DND-99 for 30 min
(Invitrogen, Carlsbad, CA, USA). Imaging was performed using a Leica DMIL
inverted fluorescence microscope (model 090-135.002, Leica Microsystems GmbH,
Wetzlar, Germany). ImageJ (NIH, Bethesda, MD, USA) was used to quantify the
number of lysosomes at various time points after light exposure, based on the
sunitinib fluorescence.33 See Supplementary Material 1.
Singlet oxygen and superoxide anion measurements. The quantum
yield for singlet oxygen photogeneration by sunitinib was determined relative to that
of TAP (absolute yield of singlet oxygen generation is 0.7) by measuring
time-resolved luminescence intensity in DMSO (Sigma-Aldrich) or acetonitrile
(Merck, Darmstadt, Germany) solutions at 1270 nm after excitation of sunitinib at
355 nm. For more information and photosensitized formation of a superoxide anion,
see Supplementary Material 2.
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Sunitinib photoactivation, image acquisition and quantification.
The chicken CAM34 vasculature was visualized and irradiated with light for the
photoactivation of sunitinib using an epi-fluorescence microscope (Nikon AG,
Eclipse E 600 FN, Tokyo, Japan) with objectives Plan Apo × 4/0.2 or Plan Fluor
× 10/0.3 (Nikon AG). Sunitinib was administered intravenously (20 μl) at a
concentration of 2 ng/embryo (0.2 μg/kg of body weight) or 12 μg/embryo
(1.2 mg/kg of body weight) into one of the main blood vessels of the CAM. One
minute after injection, a vascularized area of the CAM was irradiated (λ= 420 nm) with
a light dose of 34 J/cm2 and irradiance of 70 mW/cm2, or a dose of 130 J/cm2 and an
irradiance of 270 mW/cm2, for each sunitinib dose, respectively. The irradiated area
was delimited by an optical diaphragm at 0.02 cm2. Visualization of blood vessels was
achieved through fluorescence angiography after i.v. injection of FITC-dextran
(20 kDa, 20 μl, 25 mg/ml, (λex= 470± 20 nm, λem4520 nm) Sigma-Aldrich).
35
Image processing and quantification of the fluorescence angiographies in four
concentric areas, 1–4, was achieved using a macro written in ImageJ.36
Sunitinib and light illumination in ovarian carcinoma grown on
the CAM. A2780 human ovarian carcinoma cells (purchased from ECACC,
Salisbury, UK) were maintained at 37 °C and 5% CO2 in RPMI-1640 cell culture
medium, supplemented as above. Tumors were implanted onto the CAM on the
embryo development day 8 by preparing 25-μl hanging drops containing 1 million
A2780 cells.32 Vascularized tumors were visible 3 days after implantation, when
treatment was started. The tumors were divided into three treatment groups:
(i) control (0.1% DMSO in 0.9% NaCl; 100 μl injected i.v.), (ii) i.v. sunitinib
(12 μg/embryo; 8.75 mg/kg; assuming an embryo weight of 4.3 g, or 100 μl of
700 μM sunitinib), or (iii) i.v. sunitinib+light (12 μg/embryo; 8.75 mg/kg; drug–light
interval 1 min; light dose 40 J; light fluence 34 J/cm2 at λex= 420± 20 nm;
irradiance 270 mW/cm2).
Colo-26 tumor-bearing mice treatment. Balb/c mice (6–8 weeks old,
female, 20 g, Charles River, Orleans, France, approved by the Committee for Animal
Experiments for the Canton Vaud) were injected intradermally with 0.5 × 106
Colo-26 cells (purchased from CLS (Eppelheim, Germany) and cultured in
RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum and
antibiotics) into both flanks. When tumors were 5–6 mm in diameter, mice
received 40 mg/kg (0.1 ml) sunitinib i.p., as this dose has been previously reported.7
After 3 h, mice were anaesthetized with 2.5% isoflurane, and light treatment was
performed using an Oxxius laser (Oxxius SA, Lannion, France) coupled to an
optical fiber equipped with a frontal light distributor (Medlight SA, Ecublens,
Switzerland) at 405 nm. The applied light fluence of 35 J/cm2 was delivered at an
irradiance of 100 mW/cm2. This treatment was repeated daily for 8 consecutive
days, and tumors were measured daily. On the 9th day, mice were killed and tumors
were resected.
Immunohistochemistry. CAM tumors were resected, fixed in zinc fixative
solution,37 and stained with primary antibody for CD31 (Dianova, DIA-310,
Hamburg, Germany).32 Murine tumors were stained with primary antibody (Dianova,
Anti-Murine CD31 Antibody Clone SZ31). Then CD31 in combination with an
indirect alkaline phosphatase method was performed for 1h according to standard
procedures (Dianova).
Statistical analysis. In vitro data were analyzed for statistical significance
using the unpaired two-tailed t-test. Tumor growth curves were analyzed based on
the two-way ANOVA or two-tailed t-test. Significance was considered at *Po0.05
or **Po0.01.
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